Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Public ClinicalTrials.gov record NCT01017731. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer
Study identification
- NCT ID
- NCT01017731
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 68 participants
Conditions and interventions
Conditions
Interventions
- IMC-1121B Biological
- Moxifloxacin Drug
- Diphenhydramine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2009
- Primary completion
- Mar 31, 2010
- Completion
- Apr 30, 2014
- Last update posted
- Jun 9, 2015
2009 – 2014
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Atlanta | Georgia | 30322 | — |
| ImClone Investigational Site | Metairie | Louisiana | 70006 | — |
| ImClone Investigational Site | Ann Arbor | Michigan | 48109 | — |
| ImClone Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| ImClone Investigational Site | Providence | Rhode Island | 02903 | — |
| ImClone Investigational Site | Houston | Texas | 77024 | — |
| ImClone Investigational Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01017731, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2015 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01017731 live on ClinicalTrials.gov.